Le Lézard
Classified in: Health
Subject: MISCELLANEOUS

TELUS Mental Health Index reveals nearly one-third of workers want better control over their health


TORONTO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- TELUS Health today released its monthly TELUS Mental Health Index, revealing that workers in Canada want better control over their health and emotions. Mental health scores of those who reported having full control over their health, are significantly higher compared to those workers who reported having no control. The Index also showed that of those who have taken medication for their mental health, one-third said it took more than a year to find effective medication.

After scores holding steady for the last three months, the mental health of workers in Canada improved slightly in July by half a point, with the Mental Health Index score increasing to 65.2.

One-in-three workers in Canada (31 per cent) want more control over their health; and one-fifth (20 per cent) want more control over their emotions.

Nearly one-quarter (23 per cent) of workers in Canada have taken prescription medication for a mental health issue.

Comments from TELUS Health Chief Growth Officer, Juggy Sihota
"Having a sense of control in key areas of one's life is an important driver of mental health and wellbeing. The opportunity here for employers is to facilitate that control. Personalized flexibility and resources that address a continuum of health needs are essential to the sense of control over one's health and wellbeing. This is something that workers want. TELUS Health data previously showed that one in four workers would prefer better support for their wellbeing over a 10 per cent increase in salary. Through this period of uncertainty, employers have the ability to empower their workers in ways that will keep them healthy and passionate about the work they are doing together."

Comments from TELUS Health Global Leader, Research & Client Insights, Paula Allen
"We know that counselling is effective for mental health issues and that in certain cases, symptoms can interfere with the effectiveness of counselling. In such cases, medication is often required. It is crucial to make sure that people have the right medication, at the right time. Medication consultation and tools such as pharmacogenomic testing can help practitioners more closely match medications to a person's physical make-up to better address the issues at hand. With one in three people needing to try different medications over the course of a year or more, it is clear that a more personalized science based approach can reduce prolonged emotional angst and lost productivity associated with finding the right medication."

The full Canadian TELUS Mental Health Index report can be found here. This report includes additional insights on workplace culture, turnover and the impact of personal relationships at work amongst industries, age demographics and employment levels.

About the TELUS Mental Health Index
The survey by TELUS Health was conducted through an online survey in English and French from July 8 and July 26, 2023 with 3,000 respondents. All respondents reside in Canada and were employed within the last six months. The data has been statistically weighted to ensure the regional and gender composition of the sample reflects this population.

The TELUS Mental Health Index is based on a response scoring system that then turns individual responses into point values. Higher point values are associated with better mental health and less mental health risk.?Scores between 0 to 49 correspond with distress levels, scores between 50 to 79 correspond with strain levels and scores between 80 to 100 correspond with optimal levels of mental health.

About TELUS Health
TELUS Health is a global health care leader serving people in more than 160 countries delivering both digital innovation and clinical services to improve total physical, mental and financial health and wellness across the full spectrum of primary and preventive care. By leveraging the power of technology to deliver connected solutions and services both in-person and virtually, TELUS Health is improving access to care and revolutionizing the flow of information while facilitating collaboration, efficiency, and productivity for physicians, pharmacists, health authorities, allied health care professionals, insurers, employers and people globally, progressing its vision of transforming health care and empowering people to live healthier lives.

Our clinical team is composed of renowned and passionate health professionals around the world delivering best-in-class people-centric care to hundreds of thousands of employers, professionals and their families.

For more information, please visit: www.telushealth.com.

Media contact:

Marielle Hossack
TELUS Media Relations
[email protected]



These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: